Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immuneering Corporation (IMRX : NSDQ)
 
 • Company Description   
Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

Number of Employees: 73

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.42 Daily Weekly Monthly
20 Day Moving Average: 70,875 shares
Shares Outstanding: 29.25 (millions)
Market Capitalization: $275.52 (millions)
Beta: -1.35
52 Week High: $16.17
52 Week Low: $3.70
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 17.31% 12.87%
12 Week 31.93% 22.47%
Year To Date 94.23% 76.67%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
245 MAIN STREET SECOND FLOOR
-
CAMBRIDGE,MA 02142
USA
ph: 617-500-8080
fax: -
susan@sanoonan.com http://www.immuneering.com
 
 • General Corporate Information   
Officers
Benjamin J. Zeskind, Ph.D. - Chief Executive Officer and President
Mallory Morales - Vice President Finance and Treasurer
Ann E. Berman - Director
Robert J. Carpenter - Director
Peter Feinberg ? - Director

Peer Information
Immuneering Corporation (CORR.)
Immuneering Corporation (RSPI)
Immuneering Corporation (CGXP)
Immuneering Corporation (BGEN)
Immuneering Corporation (GTBP)
Immuneering Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45254E107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/09/23
Share - Related Items
Shares Outstanding: 29.25
Most Recent Split Date: (:1)
Beta: -1.35
Market Capitalization: $275.52 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.14 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.82
Price/Cash Flow: -
Price / Sales: 869.17
EPS Growth
vs. Year Ago Period: -4.08%
vs. Previous Quarter: -2.00%
Sales Growth
vs. Year Ago Period: -99.47%
vs. Previous Quarter: -97.37%
ROE
03/31/23 - -44.23
12/31/22 - -39.66
09/30/22 - -34.59
ROA
03/31/23 - -40.50
12/31/22 - -36.69
09/30/22 - -32.30
Current Ratio
03/31/23 - 17.05
12/31/22 - 13.50
09/30/22 - 16.54
Quick Ratio
03/31/23 - 17.05
12/31/22 - 13.50
09/30/22 - 16.54
Operating Margin
03/31/23 - -
12/31/22 - -15,932.49
09/30/22 - -9,494.86
Net Margin
03/31/23 - -
12/31/22 - -15,934.70
09/30/22 - -9,496.25
Pre-Tax Margin
03/31/23 - -38,512.78
12/31/22 - -15,935.02
09/30/22 - -9,556.92
Book Value
03/31/23 - 3.34
12/31/22 - 4.16
09/30/22 - 4.62
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©